Table 2

Individual patient visual acuity and anatomic outcomes

		BCVA LogMar		ETDRS		CMT (µm)		EDI (µm)		SFF (µm)
	Patient	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post
Group 1	CON-006	0.9	0.3	43	68	463	237	430	388	178	0
	CON-005	0.6	0.5	56	62	290	329	363	334	89	145
	CON-003	0.4	0.1	67	80	581	543	441	353	45	10
	CON-001	0.6	0.6	56	56	392	237	267	214	228	0
	CON-016	0.9	1	40	38	309	326	256	244	99	120
	CON-017	0.7	1	51	37	439	320	287	236	172	96
Group 2	CON-007	0.3	0	70	86	440	253	266	229	182	0
	CON-008	0.4	0.3	68	57	513	240	321	225	367	0
	CON-011	0.4	0.2	68	77	277	425	193	183	88	183
	CON-013	0.1	0.2	77	62	352	255	285	287	150	0
	CON-015	0.4	0.5	68	61	255	245	293	226	59	30
	CON-021	0.1	0	79	85	485	263	281	232	253	0
	Mean	0.5	0.4	61.9	64.1	399.7	306.1	306.9	262.6	159.2	48.7
	SD	0.3	0.3	12.6	16.2	103.9	93.6	72.0	63.4	92.7	67.9
	Median	0.4	0.3	67	62	392	255	287	236	150	10
	Min	0.1	0	40	37	255	237	193	183	45	0
	Max	0.9	1	77	86	581	543	441	388	367	183
	p Value	0.2112		0.5629		0.0269		0.0003		0.0186

BCVA, best-corrected visual acuity; CMT, central macular thickness; EDI, enhanced depth imaging; ETDRS, Early Treatment of Diabetic Retinopathy Study; SFF, subfoveal fluid.